Simona Lattanzi (Italy)
Marche Polytechnic University Neurological ClinicAuthor Of 1 Presentation
CAN WE PREDICT DRUG RESISTANCE IN POST-STROKE EPILEPSY
- Simona Lattanzi (Italy)
Abstract
Background and Aims:
Post-stroke epilepsy (PSE) is one of the most frequent aetiology of symptomatic epilepsy. So far, there is little evidence about the variables associated with seizure control in PSE. This study evaluated the predictors of pharmaco-resistance in patients with PSE.
Methods:
Adult patients with PSE were retrospectively identified and data on seizure occurrence were collected from medical records. The primary endpoint was the development of pharmaco-resistance defined as the failure of adequate trials of two tolerated and appropriately chosen and used antiseizure medication schedules to achieve seizure freedom.
Results:
One-hundred and fifty-nine patients with PSE were analyzed. The mean age of the patients at the time of stroke was 57 (15) years. Pharmaco-resistance occurred in 18.2% of the participants. Younger age at stroke onset (p<0.05), history of intracerebral hemorrhage (p<0.05), focal to bilateral tonic-clonic seizures (p<0.03), stroke severity (p<0.01), and status epilepticus as initial presentation of PSE (p<0.01) were independently associated with treatment refractoriness.
Conclusions:
Age at stroke onset, stroke type and severity, seizure types and status epilepticus occurrence were independent predictors of pharmaco-resistance in patients with PSE.
Presenter of 1 Presentation
CAN WE PREDICT DRUG RESISTANCE IN POST-STROKE EPILEPSY
- Simona Lattanzi (Italy)
Abstract
Background and Aims:
Post-stroke epilepsy (PSE) is one of the most frequent aetiology of symptomatic epilepsy. So far, there is little evidence about the variables associated with seizure control in PSE. This study evaluated the predictors of pharmaco-resistance in patients with PSE.
Methods:
Adult patients with PSE were retrospectively identified and data on seizure occurrence were collected from medical records. The primary endpoint was the development of pharmaco-resistance defined as the failure of adequate trials of two tolerated and appropriately chosen and used antiseizure medication schedules to achieve seizure freedom.
Results:
One-hundred and fifty-nine patients with PSE were analyzed. The mean age of the patients at the time of stroke was 57 (15) years. Pharmaco-resistance occurred in 18.2% of the participants. Younger age at stroke onset (p<0.05), history of intracerebral hemorrhage (p<0.05), focal to bilateral tonic-clonic seizures (p<0.03), stroke severity (p<0.01), and status epilepticus as initial presentation of PSE (p<0.01) were independently associated with treatment refractoriness.
Conclusions:
Age at stroke onset, stroke type and severity, seizure types and status epilepticus occurrence were independent predictors of pharmaco-resistance in patients with PSE.